SAN FRANCISCO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- A securities class-action lawsuit has been filed against Centene Corporation (NYSE: CNC), a major provider of healthcare services. The lawsuit, captioned Lunstrum v. Centene Corporation, seeks to represent investors who purchased Centene securities between December 12, 2024, and June 30, 2025. The lawsuit alleges that the company and its top executives presented a misleadingly optimistic view of its financial health, particularly concerning its enrollment and ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Centene Corporation securities between December 12, 2024, and June 30, 2025, of the September 8, 2025, deadline to become lead plaintiffs in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Centene securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court by September 8, 2025, to serve as lead plaintiff [2]. - The lawsuit alleges that Centene's management provided misleading information regarding the company's revenue guidance and earnings per share for the 2025 fiscal year, while concealing adverse facts about enrollment and morbidity rates [4]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019 alone, and has been consistently ranked among the top firms for securities class action settlements [3].

CLASS PERIOD: December 12, 2024 to June 30, 2025 ALLEGATIONS: According to the complaint, defendants provided overwhelmingly positive statements to investors while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of Centene's enrollment and morbidity rates. Investors began to question the veracity of defendants' public statements on July 1, 2025, when Centene issued a press release withdrawing 2025 guidance. Partic ...

Core Viewpoint - A lawsuit has been filed against Centene Corporation and certain senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states served by Centene [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - Centene Corporation received an unsolicited "mini-tender" offer from TRC Capital Investment Corporation to purchase up to 4 million shares at $24.75 per share, which is below the current market price [1][2] Group 1: Company Response - Centene recommends that stockholders reject TRC's offer and evaluate the current market price of their shares, advising consultation with financial advisors [2] - The company urges investors to be cautious with mini-tender offers, as they may lead to selling securities at below-market prices [2] Group 2: Offer Details - TRC's offer is set to expire on September 4th, 2025, and may be extended [1] - Investors who have already tendered their shares can withdraw them by providing written notice before the expiration of the offer [3] Group 3: Company Overview - Centene Corporation is a Fortune 500 company focused on providing integrated healthcare services, particularly to under-insured and uninsured individuals [4] - The company serves over 1 in 15 individuals in the U.S., including Medicaid and Medicare members, and offers affordable healthcare products [4]

Core Viewpoint - A lawsuit has been filed against Centene Corporation and its senior executives for potential violations of federal securities laws, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1][2]. Company Overview - Centene Corporation is a healthcare company that provides services to consumers enrolled in government-sponsored healthcare programs such as Medicaid and Medicare, as well as those purchasing insurance under the Affordable Care Act [3]. Financial Guidance and Performance - On December 12, 2024, Centene announced financial guidance for fiscal year 2025, claiming stability in earnings despite challenges [4]. - The company increased its 2025 guidance on February 4, 2025, citing enrollment overperformance, and again on April 25, 2025, due to strong growth in enrollment and retention [4]. - However, the actual market conditions showed lower than expected enrollment growth and increased morbidity rates in the majority of the states Centene serves [4]. Stock Market Reaction - On July 1, 2025, Centene withdrew its previous guidance after an independent actuarial report revealed lower than expected market growth and higher morbidity rates, leading to a significant stock price drop of $22.87 per share, or over 40%, from $56.65 to $33.78 [5].

Core Viewpoint - Centene Corporation is facing a class action lawsuit due to allegations of providing misleading statements regarding its enrollment and morbidity rates, which led to a significant decline in its stock price after the company withdrew its 2025 guidance [3][4]. Summary by Relevant Sections Allegations - The complaint claims that Centene's management made overly positive statements while concealing adverse facts about the company's true enrollment and morbidity rates [3]. - On July 1, 2025, Centene announced a withdrawal of its 2025 guidance, revealing that its market growth across 22 states was lower than expected, affecting 72% of its marketplace membership [3]. - The revised guidance indicated a reduction to approximately $1.8 billion in revenue and an adjusted diluted EPS of $2.75 [3]. Stock Performance - Following the announcement on July 1, 2025, Centene's stock price plummeted from $56.65 per share to $33.78 per share on July 2, 2025, marking a decline of 40.4% [3]. Class Action Details - The class period for the lawsuit is defined as December 12, 2024, to June 30, 2025 [3]. - Shareholders are encouraged to register for the class action by September 8, 2025, to potentially be appointed as lead plaintiffs [4]. - Participants will be enrolled in a portfolio monitoring system to receive updates on the case [4]. Law Firm Information - The Gross Law Firm is leading the class action and is recognized for protecting investors' rights against deceit and fraud [5].

SAN FRANCISCO, Aug. 18, 2025 (GLOBE NEWSWIRE) -- Before the markets opened on July 25, 2025, investors in Centene Corporation (NYSE: CNC) saw the price of their shares decline about 10% in pre-market trading after the company reported disastrous Q2 2025 financial results. For months, Centene's public statements painted a picture of expanding market share and a robust business, particularly focused on serving underinsured and uninsured populations. Yet, the lawsuit alleges that these upbeat reports were disc ...

DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material facts about the company's business, operations, and prospects. Specifically, Defendants misrepresented and/or failed to disclose that: (1) Centene's marketplace share showed lower-than-anticipated enrollment and increased aggregate market morbidity; and (2) as a result, Defendants' statements about the company's busines ...

NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of CNC during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is September 8, 2025. There is no cost or obligation to you to participate in this case. https://securitiesclasslaw.com/securities/centene-corporation-loss-submission-form/?id=161640&from=4 CLASS PERIOD: December ...